Description

Buy Keytruda (Pembrolizumab) For Sale Usa

Keytruda (pembrolizumab) is an immunotherapy medication that may be used to treat at least 19 different types of cancer such as melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), classical Hodgkin Lymphoma, endometrial carcinoma, triple-negative breast cancer, and some colorectal cancers.

• Keytruda may be used alone or together with other medicines, including chemotherapy, depending on the specific type of cancer.

Keytruda’s mechanism of action involves blocking the PD-1 protein on T cells, preventing its interaction with PD-L1 on cancer cells. This inhibition “takes the brakes off” the immune system, allowing T cells to recognize and attack cancer cells more effectively. By enhancing the body’s natural defenses, Keytruda enables a targeted immune response against tumors. Keytruda belongs to the drug class called immune checkpoint inhibitors and may also be called a monoclonal antibody.

Keytruda first gained FDA approval on September 4, 2014, for advanced melanoma. Since then, Keytruda has been approved for at least 18 different types of cancer. Buy Keytruda (Pembrolizumab) For Sale Usa

Keytruda uses

Keytruda may be used to treat the following cancers. Note that this is just a summary, see the Keytruda Prescribing Information for specific criteria and prior treatment requirements that may apply for each indication.

Melanoma: Keytruda for unresectable or metastatic melanoma OR as adjuvant treatment for Stage IIB, IIC, or III melanoma following complete resection.

Non-small cell lung cancer (NSCLC): Keytruda as first-line treatment for metastatic NSCLC with high PD-L1 expression OR in combination with chemotherapy for various NSCLC subtypes.

Head and neck squamous cell cancer (HNSCC): Keytruda for unresectable, recurrent, or metastatic HNSCC in combination with platinum and FU OR as a single agent for some other types of HNSCC.

Classical Hodgkin lymphoma (cHL): Keytruda is FDA-approved for refractory or relapsed cHL.

Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Keytruda treats refractory or relapsed PMBCL.

Urothelial cancer: Keytruda may be used in combination with other treatments or alone for advanced or metastatic urothelial carcinoma, and for some types of Bacillus Calmette-Guerin (BCG)-unresponsive urothelial cancers.

Microsatellite instability-high (MSI-H) or mismatch repair deficient cancers including colorectal cancer: Keytruda treats unresectable or metastatic MSI-H or mismatch repair deficient solid tumors.